Efficacy and Safety of Doravirine in the Rapid Initiation

Starting soon · Phase 4

Conditions studied: HIV-1-infection

In brief

Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."

Key facts

Study ID

NCT07357584

Run by

Fundación Huésped

People needed

100

Starts

2026-07-13

Expected to finish

2028-01-13

Last updated by the study team

2026-01-22

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has to voluntarily signed and dated an informed consent form, approved by an institutional ethics committee.
• ≥18 years of age.
• Not previously exposed to ARV (naïve). Subject may have received oral PrEP and PEP within the last 6 months and injectable PrEP and PEP within the last year.
• Have a received an HIV diagnosis within 30 days prior to selection. Defined as: Having confirmed HIV-1 infection. HIV-1 positive result is considered if the HIV1 RNA in plasma is ≥ 1000 copies/mL or two HIV antibody tests (using two different tests) are positive.
• NOTE: Participants may be included without knowing their baseline viral load. If baseline viral load results are less than 1000 copies/mL, the volunteer's participation will be suspended and they will be considered to have failed the screening test. A viral load brought by the subject may be considered if it was performed within the last 30 days prior to the SCR visit.
• CD4+ T-cell count: No limit.
• Subjects able to meet the protocol requirements.

You may not qualify if…

• History of hypersensitivity to doravirine, tenofovir, or lamivudine.
• Severe hepatic impairment (Child-Pugh C).
• Active HCV infection requiring specific treatment during study participation at the time of eligibility assessment. If HCV is diagnosed during the study and the participant requires treatment, the decision on whether to continue in the study will be at the investigator's discretion.
• A woman may be eligible to enter and participate in the study if she is not pregnant (confirmed by a negative urine pregnancy test at the time of screening/baseline). If the baseline visit is scheduled on a different day than the SCR, the urine pregnancy test will be repeated) or breastfeeding and if at least one of the following conditions applies:
• Women without reproductive capacity, defined as premenopausal women with tubal ligation or hysterectomy, or documented bilateral oophorectomy; or as postmenopausal women with 12 months of spontaneous amenorrhea, and women ≥ 45 years of age without hormone replacement therapy.
• Women with reproductive capacity who agree to adopt one of the contraceptive options in Appendix 2 for at least 30 days after the last dose of study medication and/or completion of the follow-up visit.
• The chosen contraceptive method must be used consistently, according to the approved product label. All study participants must be advised on safer sex practices, including the use of effective barrier methods, and the choice of effective contraceptive method must be documented in the eCRF (Electronic Case Report Form).
• The subject's general health status, in the investigator's oIPnion, interferes with the requirements of the study.
• Has a diagnosis of an active opportunistic infection defining AIDS or a malignant neoplasm within 30 days prior to evaluation (except Kaposi's sarcoma with fewer than 10 skin lesions).
• Is participating or has participated in a clinical study in the last 6 months.
• Creatinine clearance (CrCl) ≤50 mL/min according to the Cockcroft-Gault equation.
• Any verified Grade 4 abnormality (except liIPds: HDL, LDL, total cholesterol, triglycerides).
• History or presence of allergy to study drugs or their components, or to drugs in their class.
• Subjects taking any medication during the study, including over-the-counter medications and herbal preparations, without the approval of the study physician.
• Mutations resistant to doravirine, 3TC, or TDF, according to the list described below:
• DOR mutations (INNTI):
• Doravirine (INNTI) Primary: the presence of one or more ART-resistant mutations will be grounds for exclusion.
• Mutations: V106A/M, F227C/V, L234I, Y188L, Y318F, M230I/L. Secondary: the presence of one or more RAMs will be grounds for exclusion. Mutations: A98G, V108I, G190E, H221Y, P225H, F227L, P236L. Others: the presence of five or more RAMs will be grounds for exclusion. Mutations: V90I, L100I, K101E/H/P, K103N/R/S, V106I, I135T, Y181C/I/V, E138A/G/K/Q/R, V170F/T, G190A/Q/S, Y188C/H, F227I, V245E, K311R.
• NRTI (TDF) Relevant mutations: Presence of one or more RAM Mutations: K65R, insertion 69, K70R/E, Q151M,
• NRTI (3TC) Relevant mutation Presence of IM184V

Where it is running

• Fundacion IDEAA -Infectologia de atencion ambulatoria — Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
• Fundacion Huesped — Buenos Aires, Argentina

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.